Ipsen

Ipsen, founded in 2010, is a global biopharmaceutical company headquartered in France. The company specializes in engineering and developing bacterial-based protein therapeutics aimed at treating neurological, inflammatory, and endocrine diseases.

Focusing on three critical therapeutic areas—Oncology, Rare Disease, and Neuroscience—Ipsen has built a robust pipeline supported by its extensive nearly 100-year history in development and strategic global hubs in the U.S., France, and the U.K.. With an operational presence in over 40 countries, Ipsen ensures availability of its medicines in 88 countries through strategic international partnerships.

Noteworthy among its history of financial maneuvers is a $206.00M acquisition investment made on 01 July 2013, supported by Ipsen Ventures. This demonstrates the company's commitment to expanding its capabilities through external innovation.